A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab plus Standard of Care versus Placebo plus Standard of Care in Adult Subjects with Active Lupus Nephritis
Brief description of study
This is a Phase 3, multi-centre, multi-national, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of IV belimumab 10 mg/kg plus standard of care compared to placebo plus standard of care in adult subjects with active lupus nephritis. Subjects who meet the eligibility criteria during screening will be randomized to 1 of 2 treatment groups in a 1:1 ratio: 10 mg/kg belimumab plus standard of care or placebo plus standard of care.
Clinical Study Identifier: S12-02715
ClinicalTrials.gov Identifier: NCTS12-02715
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
